Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

16 mars 2020 16h08 HE | Source: Biogen Inc.

Biogen Foundation Commits $10 Million to Support COVID-19 Relief Efforts in the U.S. and Around the World

Most of the funds will be directed to support the global response and the immediate needs of communities hardest hit by COVID-19 CAMBRIDGE, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- Biogen Inc....
27 févr. 2020 16h06 HE | Source: Biogen Inc.; Sangamo Therapeutics, Inc.

Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases

Broad collaboration for gene regulation therapies in neurology, initially focused on development of ST-501 for tauopathies including Alzheimer’s disease, ST-502 for synucleinopathies including...
13 janv. 2020 07h30 HE | Source: Biogen Inc.

Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease and Parkinson’s Disease from Pfizer Inc.

PF-05251749 is a CNS-penetrant regulator of circadian rhythm with potential to address behavioral and neurological symptoms across various psychiatric and neurological diseases Biogen to pay Pfizer...
13 déc. 2019 07h30 HE | Source: Biogen Inc.

Biogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear Palsy

CAMBRIDGE, Mass., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Today, Biogen Inc. (Nasdaq: BIIB) announced topline results from the Phase 2 PASSPORT study of gosuranemab (BIIB092) for progressive supranuclear...
03 déc. 2019 07h30 HE | Source: Biogen Inc.

Biogen Announces Positive Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE)

The Phase 2 LILAC study met its primary endpoints, demonstrating statistically significant reduction of disease activity in patients with CLE and SLE who received BIIB059 compared to placeboPositive...
22 nov. 2019 07h30 HE | Source: Biogen Inc.

Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate)

CAMBRIDGE, Mass., Nov. 22, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced detailed results from the Phase 3 EVOLVE-MS-2 study demonstrating the improved patient-assessed...
21 nov. 2019 07h30 HE | Source: Biogen Inc.

Biogen Announces Enrollment Completion of Global Phase 3 Gene Therapy Study for an Inherited Retinal Disorder

CAMBRIDGE, Mass., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today the enrollment of the last patient in the global Phase 3 STAR clinical study, which is evaluating the...
06 nov. 2019 07h30 HE | Source: Biogen Inc.

Biogen to Expand Biosimilars Portfolio and Gain Access to Additional Markets Through New Transaction with Samsung Bioepis

Biogen to gain exclusive commercialization rights to two new ophthalmology biosimilars referencing Lucentis and Eylea in the U.S., Canada, Europe, Japan and AustraliaWill provide Biogen with...
04 nov. 2019 16h30 HE | Source: Biogen Inc.

Biogen to Host Investor Webcasts from Clinical Trials on Alzheimer’s Disease (CTAD) Congress on December 5, 2019

CAMBRIDGE, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) today announced it will host live webcasts of its oral presentation and a Q&A session related to its Alzheimer’s disease...
30 oct. 2019 07h30 HE | Source: Biogen Inc.

Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis

CAMBRIDGE, Mass. and DUBLIN, Ireland, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA)...

Page précédente